Gastric Cancer Market: Epidemiology and Patient-Ba

Dublin, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Gastric Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies be positioned in the gastric cancer treatment space? - Which targeted therapies are expected to experience the greatest growth over the forecast period? - How will Eli Lilly look to maintain Cyramza's first-to-market advantage? - What are the key drivers of the rapidly expanding gastric cancer market? Key Topics Covered: FORECAST: GASTRIC CANCER - Executive Summary - Market Overview and Trends - Market Definition and Methodology - Avelumab - BBI - (napabucasin) - Cyramza (ramucirumab) - GS-57 - Herceptin (trastuzumab) - Keytruda (pembrolizumab) - Lynparza (olaparib) - Nimotuzumab - Opdivo (nivolumab) - Perjeta (pertuzumab) - Primary Research Methodology TREATMENT: GASTRIC CANCER - Executive Summary - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU - Executive Summary - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: GASTRIC CANCER - Executive Summary - Product Overview - Product profile: Cyramza - Product profile: Herceptin PIPELINE: GASTRIC CANCER - Executive Summary - Clinical Pipeline Overview - Product profile (late stage): BBI6 - Product profile (late stage): GS-57 - Product profile (late stage): Keytruda - Product profile (late stage): Lynparza - Product profile (late stage): Opdivo - Product profile (late stage): Perjeta - Product profile (late stage): avelumab - Product profile (late stage): nimotuzumab For more information about this report visit http://www.researchandmarkets.com/research/m6...ric_cancer

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Oncology Drugs